# US 2003/0207347 A1 · Beta netrin and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0207347 A1
- Document ID: US20030207347A1
- Status: Published application
- Kind: A1
- Application number: 09/795,671
- Filed: 2001-02-28
- Published: 2003-11-06
- Earliest claimed: 2000-02-29
- Assignees: The General Hospital Corporation; Tufts University
- Inventors: Pamela Olson; Dale Hunter; William Brunken; Manuel Koch; Robert Burgeson
- Web page: https://patentgrep.com/patent/US20030207347A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

β-netrin nucleic acid molecules and polypeptides are provided. Methods of using the β-netrin nucleic acid molecules and polypeptides are also provided.

## Claims

### Claim 1

A substantially pure nucleic acid comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:4.

### Claim 2 (depends on 1)

The nucleic acid of claim 1 comprising the nucleotide sequence of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The nucleic acid of claim 1 comprising the nucleotide sequence of SEQ ID NO:3.

### Claim 4 (depends on 1)

The nucleic acid of claim 1 comprising the nucleotide sequence of SEQ ID NO:4.

### Claim 5 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid hybridizes under high stringency conditions to a nucleic acid which encodes the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5, or a complement thereof.

### Claim 6 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid encodes a polypeptide that reacts with an antibody specific for a Beta-netrin polypeptide.

### Claim 7

A substantially pure nucleic acid which encodes a fragment of a beta-netrin peptide of at least 50 amino acids in length.

### Claim 8

A substantially pure polypeptide which comprises at least 60% sequence identity to a beta-netrin polypeptide.

### Claim 9 (depends on 8)

The beta-netrin polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:2.

### Claim 10

A substantially pure beta-netrin polypeptide which is encoded by a nucleic acid having at least 85% sequence identity with the nucleic acid of SEQ ID NO: 1, SEQ ID NO:3, or SEQ ID NO:5.

### Claim 11 (depends on 8)

The polypeptide of claim 8, wherein the beta-netrin polypeptide has any one or more of the following properties:
(i) it includes a laminin N-terminal VI Domain;
(ii) it includes an EGF-like Domain V;
(iii) it includes a C-terminal frz domain;
(iv) it has the ability to modulate neurite outgrowth, guidance, or stability;
(v) it has the ability to modulate development of the vascular system;
(vi) it has the ability to modulate angiogenesis;
(vii) it has the ability to modulate muscular development or innervation;.
(viii) it has a molecular weight characteristic of beta-netrin of SEQ ID NO:2;
(ix) it has an overall sequence similarity of at least 60%, with a beta-netrin polypeptide of SEQ ID NO:2;
(x) it is expressed in brain, kidney, heart, or ovary; or
(xi) it is found in basement membranes of human tissues;

### Claim 12 (depends on 8)

A fragment of the beta-netrin polypeptide of claim 8 which is at least 50 amino acids in length.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7)

A vector comprising the nucleic acid of any of claims 1-7.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7)

A cell comprising the nucleic acid of any of claims 1-7.

### Claim 15

A purified preparation of an anti-beta-netrin antibody.

### Claim 16 (depends on 14)

A method for manufacture of a Beta-netrin peptide comprising culturing the cell of claim 14 in a medium to express the Beta-netrin polypeptide.

### Claim 17

An immunogen comprising a Beta-netrin polypeptide in an immunogenic preparation, the immunogen being capable of eliciting an immune response specific for the Beta-netrin polypeptide.

### Claim 18

A transgenic Beta-netrin animal.

### Claim 19

A method of modulating neuronal development, the method comprising contacting a neuron with a sufficient amount of a Beta-netrin molecule to induce neuron outgrowth, guidance, or stability, thereby modulating neuronal development.

### Claim 20 (depends on 19)

The method of claim 19, wherein the neuronal development is initiation of neurite elongation.

### Claim 21 (depends on 19)

The method of claim 19, wherein the neuron is a spinal cord, retinal, or olfactory bulb neuron.

### Claim 22

A method of modulating vascular development in a tissue, comprising contacting the tissue with a beta netrin molecule or a compound sufficient to modulate beta-netrin expression in the tissue, thereby modulating vascular development in a tissue.

### Claim 23 (depends on 22)

The method of claim 22, wherein the tissue is a cancer tissue.

### Claim 24 (depends on 22)

The method of claim 22, wherein the vascular development is angiogenesis.

### Claim 25 (depends on 24)

The method of claim 24, wherein angiogenesis is inhibited

### Claim 26

A method of modulating kidney, ovary, heart, or muscle development, the method comprising contacting a kidney, ovary, heart, or muscle cell or tissue with a Beta-netrin molecule, thereby modulating kidney, ovary, heart, or muscle development.

### Claim 27

A method of treating or preventing in a subject a Beta-netrin-related disorder, the method comprising administering to the subject an effective amount of beta-netrin molecule effective to treat or prevent the beta-netrin-related disorder in the subject.

### Claim 28

A method of determining if a subject is at risk for a disorder related to a lesion in or the misexpression of a gene which encodes a Beta-netrin polypeptide comprising detecting, in a tissue of the subject, the presence or absence of a mutation which affects the expression of the Beta-netrin gene.

### Claim 29 (depends on 28)

The method of claim 28, wherein the disorder is a vascular or neuronal disorder.

### Claim 30

A method of evaluating a compound for the ability to interact with a subject Beta-netrin polypeptide comprising contacting the compound with the subject Beta-netrin polypeptide; and evaluating ability of the compound to interact with the subject Beta-netrin polypeptide.

### Claim 31

A method of evaluating a compound for the ability to bind a nucleic acid encoding a subject Beta-netrin polypeptide, the method comprises contacting the compound with the nucleic acid and evaluating ability of the compound to form a complex with the nucleic acid.
